Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Clin Cancer Res. 2014 Dec 23;21(5):1019–1027. doi: 10.1158/1078-0432.CCR-14-2708

Table 3.

Clinical response to adoptive transfer of T cells transduced with anti-NY-ESO-1 TCR

Tumor type n(%) of patients (duration in months)
Total PR* CR OR
Synovial cell sarcoma 18 10(55)
47+,18,11,10,
8,7,5,4,3,3
1(6)
20+
11(61)
Melanoma 20 7(35)
28,10,8,6+,
5,3,3
4(20)
58+,54+,
40+, 24
11(55)

Response data updated as of December 1, 2014 or last follow-up date

*

PR – Partial response CR – Complete response OR – Objective response